Indomethacin for post-ERCP pancreatitis prophylaxis

Another attempt at the Holy Grail

Mihir S. Wagh, Stuart Sherman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.

Original languageEnglish
Pages (from-to)984-986
Number of pages3
JournalAmerican Journal of Gastroenterology
Volume102
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

Endoscopic Retrograde Cholangiopancreatography
Indomethacin
Pancreatitis
Magic
Pancreatic Ducts
Randomized Controlled Trials
Pharmacology
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Indomethacin for post-ERCP pancreatitis prophylaxis : Another attempt at the Holy Grail. / Wagh, Mihir S.; Sherman, Stuart.

In: American Journal of Gastroenterology, Vol. 102, No. 5, 05.2007, p. 984-986.

Research output: Contribution to journalArticle

@article{59e98c4981314c9899bed2eda858bb80,
title = "Indomethacin for post-ERCP pancreatitis prophylaxis: Another attempt at the Holy Grail",
abstract = "Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the {"}magic bullet{"} continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.",
author = "Wagh, {Mihir S.} and Stuart Sherman",
year = "2007",
month = "5",
doi = "10.1111/j.1572-0241.2007.01163.x",
language = "English",
volume = "102",
pages = "984--986",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Indomethacin for post-ERCP pancreatitis prophylaxis

T2 - Another attempt at the Holy Grail

AU - Wagh, Mihir S.

AU - Sherman, Stuart

PY - 2007/5

Y1 - 2007/5

N2 - Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.

AB - Acute pancreatitis continues to be the most dreaded complication after ERCP. Various risk factors for post-ERCP pancreatitis have now been recognized including patient-related, procedure-related, and operator-related factors. Numerous attempts at finding the ideal pharmacological agent for prevention of this complication have been made but nearly all drugs evaluated have failed to demonstrate clinical efficacy. Predictably, these agents have shown promise in early single-center studies but met with disappointing results when tested in larger multicenter randomized controlled trials. As the quest for the "magic bullet" continues, selecting patients with appropriate indications for ERCP and prophylactic pancreatic duct stenting in high-risk cases appears to be the best approach to averting this complication.

UR - http://www.scopus.com/inward/record.url?scp=34247898794&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247898794&partnerID=8YFLogxK

U2 - 10.1111/j.1572-0241.2007.01163.x

DO - 10.1111/j.1572-0241.2007.01163.x

M3 - Article

VL - 102

SP - 984

EP - 986

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 5

ER -